{"id":2748,"date":"2026-08-27T08:00:00","date_gmt":"2026-08-27T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2748"},"modified":"2026-08-28T16:38:07","modified_gmt":"2026-08-28T20:38:07","slug":"fda-approves-lisraya-as-first-oral-therapy-for-dermatomyositis","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2748","title":{"rendered":"FDA Approves Lisraya as First Oral Therapy for Dermatomyositis"},"content":{"rendered":"

Companies:<\/strong> Roivant Sciences \/ Priovant Therapeutics · Drug:<\/strong> Lisraya (brepocitinib) · Indication:<\/strong> Adult Dermatomyositis · Regulatory Action:<\/strong> FDA Approval · Date:<\/strong> August 27, 2026<\/p>\n

\"20260827_Roivant_Priovant_Lisraya_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

The FDA approved Priovant Therapeutics’ Lisraya (brepocitinib), a once-daily oral TYK2\/JAK1 inhibitor, for adult dermatomyositis, making it the first oral, targeted therapy approved for the disease and validating the pivotal VALOR trial’s disease-activity and steroid-sparing results.<\/p>\n

What Happened<\/h4>\n

Lisraya is dosed at 30mg once daily. The pivotal VALOR trial enrolled 241 patients over 52 weeks and met its primary endpoint, with Total Improvement Score improving by 15.3 points versus placebo (p<0.001), and all nine key secondary endpoints were also met. On a steroid-sparing measure, 55% of Lisraya-treated patients achieved moderate-or-better improvement with minimal or no steroid use, versus 30% on placebo. The label carries a boxed warning covering infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, consistent with class-wide JAK inhibitor labeling.<\/p>\n

Deep Analysis<\/h4>\n

Dermatomyositis previously had no FDA-approved targeted oral therapy; treatment relied on corticosteroids, IVIG, and off-label immunosuppressants. An approval built on a well-powered trial that met its primary endpoint and all nine pre-specified secondary endpoints represents a meaningfully de-risked dataset by autoimmune-disease standards. The boxed warning, extrapolated largely from JAK-class safety findings in rheumatoid arthritis, will shape prescribing patterns and is likely to push payers toward requiring documented steroid or conventional-therapy failure before approving Lisraya, tempering the pace of uptake even with strong efficacy data.<\/p>\n

Company and Product Background<\/h4>\n

Priovant Therapeutics is a Roivant Sciences-founded, Pfizer-partnered biotechnology company focused on autoimmune and inflammatory disease. Brepocitinib is a dual TYK2\/JAK1 inhibitor licensed from Pfizer.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Trial<\/td>\nVALOR, 241 patients, 52 weeks, randomized placebo-controlled<\/td>\n<\/tr>\n
Primary Endpoint<\/td>\nTotal Improvement Score +15.3 pts vs placebo (p<0.001)<\/td>\n<\/tr>\n
Secondary Endpoints<\/td>\nAll 9 key secondary endpoints met<\/td>\n<\/tr>\n
Steroid-Sparing<\/td>\n55% vs 30% moderate-or-better improvement with minimal\/no steroids<\/td>\n<\/tr>\n
Safety<\/td>\nBoxed warning for infections, mortality, malignancy, MACE, thrombosis (class label)<\/td>\n<\/tr>\n
Signal Type<\/td>\nFirst-in-disease regulatory approval, positive pivotal data<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A clean sweep of the primary and all nine secondary endpoints, with a steroid-sparing benefit in a disease where chronic corticosteroid use drives significant morbidity, gives physicians a genuinely differentiated tool and validates TYK2\/JAK1 inhibition as a mechanism in dermatomyositis.<\/p>\n

Bear case:<\/strong> The boxed warning inherited from the JAK inhibitor class will weigh on first-line positioning and payer access, and durability beyond 52 weeks, along with real-world safety in an often multimorbid population, remains unestablished.<\/p>\n

InSilens Take<\/h4>\n

This is a genuine unmet-need approval, dermatomyositis patients have lacked a targeted oral option, but the JAK-class boxed warning means uptake will likely track how payers position Lisraya relative to steroid-sparing thresholds rather than pure efficacy.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

The FDA approved Priovant Therapeutics’ Lisraya (brepocitinib), a once-daily oral TYK2\/JAK1 inhibitor, for adult dermatomyositis, making it the first oral, targeted therapy approved for the disease and validating the pivotal VALOR trial’s disease-activity and…<\/p>\n","protected":false},"author":1,"featured_media":2759,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[452,453,451],"class_list":["post-2748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-brepocitinib","tag-dermatomyositis","tag-priovant-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2748"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2748\/revisions"}],"predecessor-version":[{"id":2768,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2748\/revisions\/2768"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2759"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}